BRCA2 and ovarian carcinoma: OVCAR8 cells are more resistant to PARPi because of their BRCA-proficient phenotype despite heterozygous methylation on the BRCA1 promoter (27, 28), whereas PEO1 cells harbor a truncated BRCA2 mutation representing ovarian cancers deficient in DNA damage repair mechanisms (29).